Squarepoint’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Squarepoint’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,569	Closed	-$76K	–	4015
2021 Q1	$76K	Buy	+14,569	New	+$101K	﹤0.01%	2954

Other funds holding BLPH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Squarepoint's BLPH Position: Q2 2021 in Review

Squarepoint sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2021, closing a stake of 14,569 shares — an estimated $76K sold.

Squarepoint first reported a position in BLPH in Q1 2021 and held it in 1 quarter. The position peaked at $76K in Q1 2021. 27 funds tracked by Wall St. Rank hold BLPH as of Q2 2021.

Squarepoint reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Squarepoint sold 14,569 Bellerophon Therapeutics, Inc. shares in Q2 2021, an estimated $76K.
Squarepoint first reported a position in Bellerophon Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
Squarepoint's Bellerophon Therapeutics, Inc. position peaked at $76K in Q1 2021.
27 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.